The preliminary results from the Audiogene study, conducted in children aged six to 31 months without cochlear hearing implants, also showed that the SENS-501 (formerly OTOF-GT) gene therapy was ...
The AK-OTOF therapy remains in early-stage clinical testing, but the success in the first patient to receive it – an 11-year-old boy who was profoundly deaf, but whose hearing is now reported to ...
Sensorion has completed subject enrolment in the first cohort of Phase I/II Audiogene trial of gene therapy injection, SENS-501 for treating Otoferlin (OTOF) gene-mediated hearing loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback